CN Patent

CN111875638A — 一种瑞德西韦衍生物的制备方法、瑞德西韦衍生物及其应用

Assigned to Jiangsu Institute of Nuclear Medicine · Expires 2020-11-03 · 6y expired

What this patent protects

本发明公开了一种瑞德西韦衍生物的制备方法、瑞德西韦衍生物及其应用，包括制备标记前体，合成瑞德西韦衍生物 18 F‑Remdesivir，前体Remdesivir‑OTs产率达90％。 18 F‑Remdesivir标记产率2％，放化纯度大于95％。探针在血浆及PBS中稳定性良好。探针从血液和正常组织中快速消除，主要通过泌尿系统排泄。可在与新冠肺炎相关的疾病诊断及新药疗效评价等方面发挥独特作用。

USPTO Abstract

本发明公开了一种瑞德西韦衍生物的制备方法、瑞德西韦衍生物及其应用，包括制备标记前体，合成瑞德西韦衍生物 18 F‑Remdesivir，前体Remdesivir‑OTs产率达90％。 18 F‑Remdesivir标记产率2％，放化纯度大于95％。探针在血浆及PBS中稳定性良好。探针从血液和正常组织中快速消除，主要通过泌尿系统排泄。可在与新冠肺炎相关的疾病诊断及新药疗效评价等方面发挥独特作用。

Drugs covered by this patent

Patent Metadata

Patent number
CN111875638A
Jurisdiction
CN
Classification
—
Expires
2020-11-03
Drug substance claim
No
Drug product claim
No
Assignee
Jiangsu Institute of Nuclear Medicine
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.